GENFIT Joins CAC Mid 60 and SBF 120 Indices Amid Rising Market Capitalization — GENFIT S.A.

Event summary

GENFIT will be added to the CAC Mid 60 and SBF 120 indices on Euronext Paris effective September 18, 2026.
The inclusion reflects GENFIT's increased market capitalization, liquidity, and visibility.
GENFIT's CEO Pascal Prigent cited growing investor confidence in the company's strategy and execution.
The company's admission to the SBF 120 is expected to enhance its profile among institutional investors.
GENFIT's market capitalization and liquidity have been key factors in its inclusion in these indices.

The big picture

GENFIT's inclusion in the CAC Mid 60 and SBF 120 indices underscores its growing relevance within the French equity market. The move comes amid a broader trend of biopharmaceutical companies enhancing their market positioning through strategic milestones. With Ipsen as a significant shareholder, GENFIT's ability to execute on its strategy and deliver innovative therapies will be closely watched by investors.

What we're watching

Market Positioning: How GENFIT's inclusion in the CAC Mid 60 and SBF 120 indices will affect its visibility and attractiveness to institutional investors.
Investor Confidence: Whether the growing investor confidence in GENFIT's strategy and execution will translate into sustained share price appreciation.
Execution Risk: The pace at which GENFIT can advance its pipeline and deliver on its strategic commitments following this milestone.